Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycine/lysine acetylsalicylate inhalation - Ventaleon

Next Previous
Drug Profile

Glycine/lysine acetylsalicylate inhalation - Ventaleon

Alternative Names: Acti-INSP-001; Glycine/lysine acetylsalicylate inhalation - Vectura; LASAG; Lysine acetylsalicylate glycine inhalation - Vectura; Lysine acetylsalicylate/glycine inhalation - Vectura; VR 736

Latest Information Update: 29 Jul 2016

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Activaero GmbH
  • Developer Vectura; Ventaleon
  • Class Antiplatelets; Antipyretics; Antirheumatics; Antivirals; Basic amino acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates; Small molecules
  • Mechanism of Action Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 29 Jul 2016 Glycine/lysine acetylsalicylate inhalation is still in phase II trials in Influenza virus infections (in hospitalised patients) (Vectura pipeline, July 2016)
  • 13 Mar 2014 Activaero GmbH has been acquired by Vectura
  • 12 Feb 2013 Phase-II clinical trials in Influenza virus infections (in hospitalised patients) in Latvia, Lithuania and Spain (Inhalation)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top